SCHEMBL4045920

SCHEMBL4045920

COc1ccc2c(c1)Cc1c-2n[nH]c1Nc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.65
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
ACHE P22303 3/20 0.49
KDM4E B2RXH2 2/20 0.49
ALPL P05186 1/20 0.49
CLK1 P49759 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
HIF1A Q16665 2/20 0.47
ATM Q13315 1/20 0.47
MAPK14 Q16539 1/20 0.46
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA4 P22748 2/20 0.45
CA6 P23280 2/20 0.45
MAPT P10636 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041860 0.93 PDGFRB (0.65) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4051452 0.88 PDGFRB (0.51) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4050263 0.88 PDGFRB (0.51) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4043559 0.88 PDGFRB (0.53) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL13887540 0.87 PDGFRB (0.50) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4047622 0.86 PDGFRB (0.49) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4047495 0.85 PDGFRB (0.48) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4041878 0.85 PDGFRB (0.48) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4047927 0.85 PDGFRB (0.55) PDGFRBMEN1KMT2AACHEKDM4E
SCHEMBL4046777 0.85 HIF1A (0.49) PDGFRBMEN1KMT2AKDM4EALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
EP-1506175-B1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders PDGFRA, PDGFRB, PDGFA PDGFRB 2/4885MEN1 2796/4885KMT2A 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.